Regeneron Pharmaceuticals Sees Increased Investment from Rhenman & Partners

Biotech firm's shares purchased by Swedish asset management firm

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Rhenman & Partners Asset Management AB, a Swedish institutional investor, increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 30.3% during the third quarter of 2025. The firm now owns 36,100 shares of the biopharmaceutical company's stock, valued at approximately $20.3 million.

Why it matters

Regeneron is a prominent biotech firm known for its innovative drug discovery technologies and pipeline of biologic therapies. The increased investment from Rhenman & Partners suggests confidence in the company's long-term growth prospects, which could signal positive sentiment among institutional investors.

The details

According to a regulatory filing, Rhenman & Partners Asset Management AB purchased an additional 8,400 shares of Regeneron Pharmaceuticals during the third quarter. This brings the firm's total position in the company to 36,100 shares, representing approximately 2.2% of its overall investment portfolio.

  • Rhenman & Partners increased its stake in Regeneron Pharmaceuticals during the third quarter of 2025.

The players

Rhenman & Partners Asset Management AB

A Swedish institutional investor and asset management firm.

Regeneron Pharmaceuticals, Inc.

A U.S.-based biotechnology company focused on discovering, developing, and commercializing innovative medicines for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

Regeneron's ability to attract increased investment from a prominent European asset manager underscores the company's strong position in the biotech industry and its potential for continued growth and innovation.